NCT06761911View on ClinicalTrials.gov

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 17, 2025

Study Completion Date

January 31, 2026

Conditions
Hodgkin Lymphoma (Category)
Interventions
DRUG

Brentuximab Vedotin (Bv)

1.2mg/kg/2w or 1.8mg/kg/3w

DRUG

Sintilimab

200mg/3w

DRUG

Tislelizumab

200mg/3w

DRUG

Bendamustine

90mg/m2/3w

All Listed Sponsors
lead

Xiuhua Sun

OTHER